1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Inhalers - Medical Devices Pipeline Assessment, 2015

Inhalers - Medical Devices Pipeline Assessment, 2015

  • December 2015
  • -
  • Global Data
  • -
  • 125 pages

Inhalers - Medical Devices Pipeline Assessment, 2015

Summary

GlobalData's Medical Devices sector report, “Inhalers - Medical Devices Pipeline Assessment, 2015" provides an overview of Inhalers currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalers pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Inhalers under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Inhalers under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Inhalers - Medical Devices Pipeline Assessment, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 7
2 Introduction 8
2.1 Inhalers Overview 8
3 Products under Development 9
3.1 Inhalers - Pipeline Products by Stage of Development 9
3.2 Inhalers - Pipeline Products by Segment 10
3.3 Inhalers - Pipeline Products by Territory 11
3.4 Inhalers - Pipeline Products by Regulatory Path 12
3.5 Inhalers - Pipeline Products by Estimated Approval Date 13
3.6 Inhalers - Ongoing Clinical Trials 14
4 Inhalers - Pipeline Products under Development by Companies 15
4.1 Inhalers Companies - Pipeline Products by Stage of Development 15
4.2 Inhalers - Pipeline Products by Stage of Development 17
5 Inhalers Companies and Product Overview 19
5.1 Adamis Pharmaceuticals Corporation Company Overview 19
5.1.1 Adamis Pharmaceuticals Corporation Pipeline Products and Ongoing Clinical Trials Overview 19
5.2 Advent Pharmaceuticals Pty Ltd Company Overview 22
5.2.1 Advent Pharmaceuticals Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview 22
5.3 Aespira Ltd. Company Overview 23
5.3.1 Aespira Ltd. Pipeline Products and Ongoing Clinical Trials Overview 23
5.4 Akela Pharma Inc. (Inactive) Company Overview 24
5.4.1 Akela Pharma Inc. (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 24
5.5 Alexza Pharmaceuticals, Inc. Company Overview 25
5.5.1 Alexza Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
5.6 Bayer HealthCare AG Company Overview 28
5.6.1 Bayer HealthCare AG Pipeline Products and Ongoing Clinical Trials Overview 28
5.7 Bellerophon Therapeutics LLC Company Overview 30
5.7.1 Bellerophon Therapeutics LLC Pipeline Products and Ongoing Clinical Trials Overview 30
5.8 Bespak Europe Ltd. Company Overview 31
5.8.1 Bespak Europe Ltd. Pipeline Products and Ongoing Clinical Trials Overview 31
5.9 Cipla Ltd. Company Overview 32
5.9.1 Cipla Ltd. Pipeline Products and Ongoing Clinical Trials Overview 32
5.10 CN Creative Company Overview 34
5.10.1 CN Creative Pipeline Products and Ongoing Clinical Trials Overview 34
5.11 Drexel University Company Overview 35
5.11.1 Drexel University Pipeline Products and Ongoing Clinical Trials Overview 35
5.12 FocusStart Orthosensors Company Overview 36
5.12.1 FocusStart Orthosensors Pipeline Products and Ongoing Clinical Trials Overview 36
5.13 GlaxoSmithKline Plc Company Overview 37
5.13.1 GlaxoSmithKline Plc Pipeline Products and Ongoing Clinical Trials Overview 37
5.14 Hovione FarmaCiencia SA Company Overview 39
5.14.1 Hovione FarmaCiencia SA Pipeline Products and Ongoing Clinical Trials Overview 39
5.15 MannKind Corporation Company Overview 40
5.15.1 MannKind Corporation Pipeline Products and Ongoing Clinical Trials Overview 40
5.16 Medihale Ltd. Company Overview 42
5.16.1 Medihale Ltd. Pipeline Products and Ongoing Clinical Trials Overview 42
5.17 Nanotherapeutics, Inc. Company Overview 43
5.17.1 Nanotherapeutics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 43
5.18 Nektar Therapeutics Company Overview 45
5.18.1 Nektar Therapeutics Pipeline Products and Ongoing Clinical Trials Overview 45
5.19 North Carolina State University Company Overview 47
5.19.1 North Carolina State University Pipeline Products and Ongoing Clinical Trials Overview 47
5.20 Novartis AG Company Overview 48
5.20.1 Novartis AG Pipeline Products and Ongoing Clinical Trials Overview 48
5.21 OPKO Health, Inc. Company Overview 52
5.21.1 OPKO Health, Inc. Pipeline Products and Ongoing Clinical Trials Overview 52
5.22 Pharmaxis Limited Company Overview 54
5.22.1 Pharmaxis Limited Pipeline Products and Ongoing Clinical Trials Overview 54
5.23 Respira Therapeutics, Inc. Company Overview 56
5.23.1 Respira Therapeutics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
5.24 Sandoz International GmbH Company Overview 57
5.24.1 Sandoz International GmbH Pipeline Products and Ongoing Clinical Trials Overview 57
5.25 Sheffield Hallam University Company Overview 60
5.25.1 Sheffield Hallam University Pipeline Products and Ongoing Clinical Trials Overview 60
5.26 Shin Nippon Biomedical Laboratories, Ltd. Company Overview 61
5.26.1 Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 61
5.27 SHL Medical Company Overview 63
5.27.1 SHL Medical Pipeline Products and Ongoing Clinical Trials Overview 63
5.28 SkyePharma Plc Company Overview 65
5.28.1 SkyePharma Plc Pipeline Products and Ongoing Clinical Trials Overview 65
5.29 Teva Pharmaceutical Industries Limited Company Overview 67
5.29.1 Teva Pharmaceutical Industries Limited Pipeline Products and Ongoing Clinical Trials Overview 67
5.30 University of Kansas Company Overview 71
5.30.1 University of Kansas Pipeline Products and Ongoing Clinical Trials Overview 71
5.31 University of Texas Medical Branch at Galveston Company Overview 72
5.31.1 University of Texas Medical Branch at Galveston Pipeline Products and Ongoing Clinical Trials Overview 72
6 Inhalers- Recent Developments 73
7 Appendix 122
7.1 Methodology 122
7.2 About GlobalData 124
7.3 Contact Us 125
7.4 Disclaimer 125

1.1 List of Tables
Table 1: Inhalers - Pipeline Products by Stage of Development 9
Table 2: Inhalers - Pipeline Products by Segment 10
Table 3: Inhalers - Pipeline Products by Territory 11
Table 4: Inhalers - Pipeline Products by Regulatory Path 12
Table 5: Inhalers - Pipeline Products by Estimated Approval Date 13
Table 6: Inhalers - Ongoing Clinical Trials 14
Table 7: Inhalers Companies - Pipeline Products by Stage of Development 15
Table 8: Inhalers - Pipeline Products by Stage of Development 17
Table 9: Adamis Pharmaceuticals Corporation Pipeline Products and Ongoing Clinical Trials Overview 19
Table 10: 3M Taper Dry Powder Inhaler - Product Status 20
Table 11: 3M Taper Dry Powder Inhaler - Product Description 20
Table 12: APC-5000 - Dry Powder Inhaler - Product Status 21
Table 13: APC-5000 - Dry Powder Inhaler - Product Description 21
Table 14: Advent Pharmaceuticals Pty Ltd Pipeline Products and Ongoing Clinical Trials Overview 22
Table 15: g60 Dry Powder Inhaler - Product Status 22
Table 16: g60 Dry Powder Inhaler - Product Description 22
Table 17: Aespira Ltd. Pipeline Products and Ongoing Clinical Trials Overview 23
Table 18: resQhaler - Product Status 23
Table 19: resQhaler - Product Description 23
Table 20: Akela Pharma Inc. (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 24
Table 21: Fentanyl TAIFUN Inhaler - Product Status 24
Table 22: Fentanyl TAIFUN Inhaler - Product Description 24
Table 23: Alexza Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
Table 24: Staccato System - Disposable Single Dose - Product Status 26
Table 25: Staccato System - Disposable Single Dose - Product Description 26
Table 26: Staccato System - Multiple Dose - Product Status 27
Table 27: Staccato System - Multiple Dose - Product Description 27
Table 28: Bayer HealthCare AG Pipeline Products and Ongoing Clinical Trials Overview 28
Table 29: Ciprofloxacin Dry Powder Inhaler - Product Status 29
Table 30: Ciprofloxacin Dry Powder Inhaler - Product Description 29
Table 31: Bellerophon Therapeutics LLC Pipeline Products and Ongoing Clinical Trials Overview 30
Table 32: Mark2 Device - Product Status 30
Table 33: Mark2 Device - Product Description 30
Table 34: Bespak Europe Ltd. Pipeline Products and Ongoing Clinical Trials Overview 31
Table 35: DEV610 - Product Status 31
Table 36: DEV610 - Product Description 31
Table 37: Cipla Ltd. Pipeline Products and Ongoing Clinical Trials Overview 32
Table 38: Synchrobreathe - Product Status 33
Table 39: Synchrobreathe - Product Description 33
Table 40: CN Creative Pipeline Products and Ongoing Clinical Trials Overview 34
Table 41: Nicadex Electronic Inhaler - Product Status 34
Table 42: Nicadex Electronic Inhaler - Product Description 34
Table 43: Drexel University Pipeline Products and Ongoing Clinical Trials Overview 35
Table 44: BREATHE Inhaler - Product Status 35
Table 45: BREATHE Inhaler - Product Description 35
Table 46: FocusStart Orthosensors Pipeline Products and Ongoing Clinical Trials Overview 36
Table 47: Smart Inhaler - Product Status 36
Table 48: Smart Inhaler - Product Description 36
Table 49: GlaxoSmithKline Plc Pipeline Products and Ongoing Clinical Trials Overview 37
Table 50: Gemini Multi-Dose Combination Inhaler - Product Status 38
Table 51: Gemini Multi-Dose Combination Inhaler - Product Description 38
Table 52: Hovione FarmaCiencia SA Pipeline Products and Ongoing Clinical Trials Overview 39
Table 53: XCaps - Product Status 39
Table 54: XCaps - Product Description 39
Table 55: MannKind Corporation Pipeline Products and Ongoing Clinical Trials Overview 40
Table 56: Dreamboat - Product Status 41
Table 57: Dreamboat - Product Description 41
Table 58: Medihale Ltd. Pipeline Products and Ongoing Clinical Trials Overview 42
Table 59: Toucan Multi-Dose Inhaler - Product Status 42
Table 60: Toucan Multi-Dose Inhaler - Product Description 42
Table 61: Nanotherapeutics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 43
Table 62: GelVac Intranasal Powder Vaccine Delivery System - Product Status 43
Table 63: GelVac Intranasal Powder Vaccine Delivery System - Product Description 43
Table 64: NanoGENT - Product Status 44
Table 65: NanoGENT - Product Description 44
Table 66: Nektar Therapeutics Pipeline Products and Ongoing Clinical Trials Overview 45
Table 67: Nektar Dry Powder Inhaler - Amikacin - Product Status 46
Table 68: Nektar Dry Powder Inhaler - Amikacin - Product Description 46
Table 69: North Carolina State University Pipeline Products and Ongoing Clinical Trials Overview 47
Table 70: Smart Inhaler System - Product Status 47
Table 71: Smart Inhaler System - Product Description 47
Table 72: Novartis AG Pipeline Products and Ongoing Clinical Trials Overview 48
Table 73: Ultibro Breezhaler - Product Status 49
Table 74: Ultibro Breezhaler - Product Description 49
Table 75: Novartis AG - Ongoing Clinical Trials Overview 50
Table 76: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD 51
Table 77: OPKO Health, Inc. Pipeline Products and Ongoing Clinical Trials Overview 52
Table 78: Inspiromatic - Product Status 53
Table 79: Inspiromatic - Product Description 53
Table 80: Pharmaxis Limited Pipeline Products and Ongoing Clinical Trials Overview 54
Table 81: Orbital Dry Powder Inhaler - Product Status 55
Table 82: Orbital Dry Powder Inhaler - Product Description 55
Table 83: Respira Therapeutics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
Table 84: Dry Powder Inhaler - Product Status 56
Table 85: Dry Powder Inhaler - Product Description 56
Table 86: Sandoz International GmbH Pipeline Products and Ongoing Clinical Trials Overview 57
Table 87: Solis Multi-Dose Dry Powder Inhaler - Product Status 58
Table 88: Solis Multi-Dose Dry Powder Inhaler - Product Description 58
Table 89: Unit-Dose Dry Powder Inhaler - Product Status 59
Table 90: Unit-Dose Dry Powder Inhaler - Product Description 59
Table 91: Sheffield Hallam University Pipeline Products and Ongoing Clinical Trials Overview 60
Table 92: Dry Powder Inhaler - Product Status 60
Table 93: Dry Powder Inhaler - Product Description 60
Table 94: Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products and Ongoing Clinical Trials Overview 61
Table 95: µco System - Product Status 62
Table 96: µco System - Product Description 62
Table 97: SHL Medical Pipeline Products and Ongoing Clinical Trials Overview 63
Table 98: Breath Operated Inhaler - Product Status 63
Table 99: Breath Operated Inhaler - Product Description 63
Table 100: TobrAir - Product Status 64
Table 101: TobrAir - Product Description 64
Table 102: SkyePharma Plc Pipeline Products and Ongoing Clinical Trials Overview 65
Table 103: Flutiform Breath-Actuated Inhaler - Product Status 66
Table 104: Flutiform Breath-Actuated Inhaler - Product Description 66
Table 105: Teva Pharmaceutical Industries Limited Pipeline Products and Ongoing Clinical Trials Overview 67
Table 106: QVAR Breath-actuated Inhaler (BAI) - Product Status 68
Table 107: QVAR Breath-actuated Inhaler (BAI) - Product Description 68
Table 108: Spiromax EU / mDPI US - Product Status 69
Table 109: Spiromax EU / mDPI US - Product Description 69
Table 110: Tidal Inhaler - Product Status 70
Table 111: Tidal Inhaler - Product Description 70
Table 112: University of Kansas Pipeline Products and Ongoing Clinical Trials Overview 71
Table 113: Dry Powder Inhaler - Product Status 71
Table 114: Dry Powder Inhaler - Product Description 71
Table 115: University of Texas Medical Branch at Galveston Pipeline Products and Ongoing Clinical Trials Overview 72
Table 116: Dry Powder Drug Delivery System - Product Status 72
Table 117: Dry Powder Drug Delivery System - Product Description 72
Table 118: Glossary 123

1.2 List of Figures
Figure 1: Inhalers - Pipeline Products by Stage of Development 9
Figure 2: Inhalers - Pipeline Products by Segment 10
Figure 3: Inhalers - Pipeline Products by Territory 11
Figure 4: Inhalers - Pipeline Products by Regulatory Path 12
Figure 5: Inhalers - Pipeline Products by Estimated Approval Date 13
Figure 6: Inhalers - Ongoing Clinical Trials 14

Companies mentioned
Adamis Pharmaceuticals Corporation
Advent Pharmaceuticals Pty Ltd
Aespira Ltd.
Akela Pharma Inc.
Alexza Pharmaceuticals, Inc.
Bayer HealthCare AG
Bellerophon Therapeutics LLC
Bespak Europe Ltd.
Cipla Ltd.
CN Creative
Drexel University
FocusStart Orthosensors
GlaxoSmithKline Plc
Hovione FarmaCiencia SA
MannKind Corporation
Medihale Ltd.
Nanotherapeutics, Inc.
Nektar Therapeutics
North Carolina State University
Novartis AG
OPKO Health, Inc.
Pharmaxis Limited
Respira Therapeutics, Inc.
Sandoz International GmbH
Sheffield Hallam University
Shin Nippon Biomedical Laboratories, Ltd.
SHL Medical
SkyePharma Plc
Teva Pharmaceutical Industries Limited
University of Kansas
University of Texas Medical Branch at Galveston

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...

North America Insulin Delivery Market Outlook to 2022

North America Insulin Delivery Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by Global Data

North America Insulin Delivery Market Outlook to 2022 Summary GlobalData’s new report, "North America Insulin Delivery Market Outlook to 2022", provides key market data on the North America Insulin Delivery ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.